drug · small molecule
rucaparib camsylate
Marketedupdated 5mo agoby pharmaand GmbH🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
targets
PARP 1, 2 and 3
all catalysts(9)
approval · 9
Dec 19, 2016
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Apr 6, 2018
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
May 15, 2020
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Oct 8, 2020
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Sep 30, 2021
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Jun 10, 2022
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Dec 21, 2022
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Dec 17, 2025
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Dec 17, 2025
approval
RUBRACA (RUCAPARIB CAMSYLATE) — FDA approval
rucaparib camsylate
→
Trials studying rucaparib camsylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 12, 2027
316 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (27)
- Aug 17, 2035method-of-use (U-2830)US 10130636
- Aug 17, 2035method-of-use (U-2830)US 10130636
- Aug 17, 2035method-of-use (U-2012)US 10130636
- Aug 17, 2035formulationUS 9987285
- Aug 17, 2035formulationUS 9987285
- Aug 17, 2035formulationUS 9987285
- Aug 4, 2031method-of-use (U-2830)US 88595624.8y
- Aug 4, 2031method-of-use (U-2830)US 88595624.8y
- Aug 4, 2031method-of-use (U-2830)US 88595624.8y
- Feb 10, 2031formulationUS 102789744.4y
- Feb 10, 2031formulationUS 102789744.4y
- Feb 10, 2031formulationUS 102789744.4y
- Feb 10, 2031compositionUS 87540724.4y
- Feb 10, 2031compositionUS 87540724.4y
- Feb 10, 2031compositionUS 87540724.4y
- Feb 10, 2031compositionUS 90454874.4y
- Feb 10, 2031compositionUS 90454874.4y
- Feb 10, 2031compositionUS 90454874.4y
- Feb 10, 2031method-of-use (U-2273)US 98616384.4y
- Feb 10, 2031method-of-use (U-2012)US 98616384.4y
- Feb 10, 2031method-of-use (U-2273)US 98616384.4y
- Aug 12, 2027method-of-use (U-2830)US 8071579316d
- Aug 12, 2027method-of-use (U-2830)US 8071579316d
- Aug 12, 2027method-of-use (U-2830)US 8071579316d
- Aug 12, 2027method-of-use (U-2830)US 8143241316d
- Aug 12, 2027method-of-use (U-2830)US 8143241316d
- Aug 12, 2027method-of-use (U-2830)US 8143241316d
FDA exclusivities (3)
- Dec 17, 2028I-982Indication (3y)2.2y
- Dec 17, 2028I-982Indication (3y)2.2y
- Dec 17, 2028I-982Indication (3y)2.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that